Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490127 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL20158324 | 0.70 | TSHR (0.40) | ALDH1A1TSHR | |
| SCHEMBL22532445 | 0.66 | — | — | |
| SCHEMBL3956871 | 0.66 | — | — | |
| SCHEMBL12372437 | 0.65 | ACLY (0.31) | ALDH1A1TSHR | |
| SCHEMBL3533080 | 0.65 | TSHR (0.35) | ALDH1A1TSHR | |
| SCHEMBL7064786 | 0.64 | — | — | |
| SCHEMBL935231 | 0.64 | — | — | |
| SCHEMBL536361 | 0.61 | — | — | |
| SCHEMBL1285864 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790209-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20160340343-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| WO-2016109362-A1 | CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20150225373-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| EP-2890695-A2 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014033447-A2 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225373-A1 | KINASE INHIBITORS | SYK, SRC, BTK | ALDH1A1 2504/4885TSHR 1980/4885 |
| US-20160340343-A1 | KINASE INHIBITORS | SYK, LYN, BTK | ALDH1A1 2404/4885TSHR 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.